Search
AZN.LN: Head and neck hold may explain BMYs hesitance with combo
Head and neck specific?
The FDA placed a partial clinical trial hold on recruiting new patients to AstraZeneca’s anti PD-L1 (durvalumab) monotherapy and combination with anti CTLA4 (tremelimumab) in 1st and 2nd line head and Neck cancer. This followed Astra’s observation of bleeding cases seen in both the 1st line KESTREL and 2nd line EAGLE head and neck studies. Read through to MYSTIC....
